Purinostat mesylate efficiently attenuated Ph<sup>+</sup> B-ALL progression and significantly prolonged the survival both in BL-2 secondary transplantation model with clinical patient symptoms of Ph<sup>+</sup> B-ALL, <i>BCR-ABL(T315I)</i>-induced primary B-ALL mouse model, and PDX model derived from patients with relapsed Ph<sup>+</sup> B-ALL post TKI treatment.
Using BCR-ABL-expressing myelogenous and lymphoid cell lines and mouse models of CML and B-cell acute lymphoblastic leukemia (B-ALL) induced by wild-type BCR-ABL or T315I mutant-BCR-ABL, we evaluated the inhibitory effects of omacetaxine on CML and B-ALL.